What Evidence Can and Cannot Show About Tysabri and PML

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Science to Targeted Risk Awareness

If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). Recognizing early symptoms like vision changes or weakness is critical. The legacy of pharmacovigilance research has long provided a framework for understanding drug risks, and this page reviews what FAERS evidence can—and cannot—tell us about PML symptoms to track.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its use is associated with a significantly increased risk of progressive multifocal leukoencephalopathy (PML), a rare but often fatal brain infection caused by the JC virus. The following narrative integrates clinical, pharmacological, and risk-related evidence to inform patients and their families about the medical and legal dimensions of this association. Progressive multifocal leukoencephalopathy is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals. The disease is caused by the JC virus (JCV) and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive decline, visual loss, and speech difficulties. Diagnosis is confirmed through brain imaging and detection of JCV DNA in cerebrospinal fluid. The condition is often rapidly progressive, and treatment options are limited, focusing on immune reconstitution and supportive care.

Mechanism of PML Induction by Tysabri

Tysabri is a monoclonal antibody that binds to alpha-4 integrins, preventing immune cells from crossing the blood-brain barrier. While this mechanism reduces inflammation in the central nervous system, it also impairs immune surveillance against latent viruses, including JCV. The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy. The mechanistic pathway linking Tysabri to PML involves reactivation of latent JCV in the brain due to reduced immune surveillance. Normally, JCV is controlled by T cells that patrol the central nervous system. By blocking lymphocyte migration, Tysabri allows the virus to replicate unchecked, leading to lytic infection of oligodendrocytes and subsequent demyelination. This process can occur months to years after starting treatment, with the risk increasing over time.

Legal and Settlement Considerations in California

The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling also mandates enrollment in the TOUCH Prescribing Program, a restricted distribution system designed to ensure that patients are informed of the risks and monitored for symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients and their families have alleged that the warnings were insufficient or that the risks were not adequately communicated, leading to claims for compensation. Settlement-related considerations for affected patients include the need to document the timeline between Tysabri exposure and the onset of PML symptoms. The duration of treatment prior to PML onset can range from a few months to several years, as seen with other serious infections associated with Tysabri, such as herpes encephalitis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In California, patients diagnosed with PML after receiving Tysabri may pursue legal action against the manufacturer, alleging failure to warn or design defect. Settlements in such cases often consider the severity of the injury, the degree of disability, and the adequacy of the warnings provided.

Clinical Management and Prognosis

The timeline between exposure and documented harm is critical for establishing causation. PML typically develops after prolonged Tysabri use, with the highest risk after two years of treatment. Patients who test positive for anti-JCV antibodies and have received prior immunosuppressants are at even greater risk. Once PML is suspected, Tysabri should be withheld immediately (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, even with prompt discontinuation, the disease can progress, leading to permanent neurological deficits or death. In summary, the association between Tysabri and PML is well-established through clinical evidence and FDA warnings. Patients and their families should be aware of the risk factors, the need for vigilant monitoring, and the potential for legal recourse if harm occurs. The evidence underscores the importance of informed consent and the role of restricted distribution programs in managing this serious adverse effect.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Tysabri and Progressive Multifocal Leukoencephalopathy?

Tysabri (natalizumab) is a biologic therapy that increases the risk of PML, a rare brain infection caused by the JC virus. The FDA boxed warning states that Tysabri increases the risk of PML, which usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Risk factors include anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use.

What legal options are available for California patients who developed PML after Tysabri?

Patients in California diagnosed with PML after Tysabri use may pursue legal action against the manufacturer for failure to warn or design defect. Settlements consider injury severity, disability, and adequacy of warnings. Documenting the timeline between Tysabri exposure and PML onset is critical for establishing causation.

How is PML diagnosed and what are the symptoms?

PML is diagnosed through brain imaging and detection of JCV DNA in cerebrospinal fluid. Symptoms include progressive weakness, gait disturbance, cognitive decline, visual loss, and speech difficulties. The condition is often rapidly progressive with limited treatment options.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Tysabri Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.